| Literature DB >> 33313145 |
Jianyu He1,2, Yuan Pang1,2, Huayu Yang3, Kevin Montagne4, Marie Shinohara5, Yilei Mao3, Wei Sun1,2,6, Yasuyuki Sakai7.
Abstract
BACKGROUND: In liver tissue engineering, co-culturing hepatocytes with typical non-parenchymal hepatic cells to form cell aggregates is available to mimic the in vivo microenvironment and promote cell biological functions. With a modular assembly approach, endothelialized hepatic cell aggregates can be packed for perfusion culture, which enables the construction of large-scale liver tissues. Since tightly packed aggregates tend to fuse with each other and block perfusion flows, a loosely packed mode was introduced in our study.Entities:
Keywords: Co-culture; HepG2; Swiss 3T3; modular assembly; perfusion culture
Year: 2020 PMID: 33313145 PMCID: PMC7723527 DOI: 10.21037/atm-20-1598
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Formation of endothelialized hepatic cell aggregates in a polydimethylsiloxane (PDMS)-based oxygen-permeable microwell device. (A) Structure of the PDMS-based oxygen-permeable microwell device. (B) Detailed structure of a microwell membrane. (C) Schematic showing the process of co-culturing hepatocellular carcinoma (HepG2) cells, Swiss 3T3 cells, and human umbilical vein endothelial cells (HUVECs) in the microwell device.
Figure 2Preparation of biodegradable poly-L-lactic acid (PLLA) scaffold fibers. (A) Non-woven PLLA fabric (20 g/m2). (B) Single PLLA fibers in the suspension (short fibers: 20–50 µm, medium fibers: 50–200 µm, long fibers: 200–300 µm).
Figure 3Perfusion culture system. (A) Structure of the PDMS-based bioreactor (cross-sectional view in the left schematic figure). (B) Configuration of the perfusion culture system.
Figure 4Swiss 3T3 cells facilitated the formation of hepatic cell aggregates. (A) Images of pure HepG2 aggregates (left) and HepG2/Swiss 3T3 co-cultured aggregates (right) after 20 h of cell inoculation. (B) Average diameter of pure HepG2 aggregates and co-cultured aggregates. (C) Spheroid circularity of pure HepG2 aggregates and co-cultured aggregates (scale bar: 100 µm) (*, P<0.05; **, P<0.01).
Figure 5Endothelialization of hepatic cell aggregates in the microwell device. (A) Fluorescent images showing the distribution of Swiss 3T3 cells (green) and HUVECs (red) in microwell chambers. (B) Magnified fluorescent images showing the detailed distribution of Swiss 3T3 cells (green) and HUVECs (red) in a single aggregate. (C) An immunofluorescent image illustrating VE-cadherin expression by HUVECs (scale bar: 100 µm).
Distribution of fiber length in the suspension
| Fiber length (μm) | 20−50 | 50−100 | 100−150 | 150−200 | 200−250 | 250−300 |
|---|---|---|---|---|---|---|
| Proportion (%) | 28.49 | 18.44 | 15.64 | 9.50 | 15.64 | 12.29 |
| Degree | Short | Medium | Medium | Medium | Long | Long |
Figure 6Measurement of cell proliferation and liver-specific functions during the perfusion culture. (A) Cell number of aggregates on day 1 and day 7. (B) Glucose consumption rate of aggregates in seven days of culture. (C) Albumin secretion of aggregates in seven days of culture (***, P<0.001).
Figure 7Histological morphology of aggregates in the bioreactor after 10 days of perfusion culture. (A) Pure HepG2 aggregates. (B) Endothelialized hepatic cell aggregates (HepG2/Swiss 3T3/HUVECs) (scale bar: 100 µm).